COMPREHENSIVE PUBMED ANALYSIS REPORT - MASLD PROJECT
============================================================

STUDY OVERVIEW
--------------------
Analysis Date: 2025-11-01 19:44
Data Source: pubmed_masld_articles_20251101_1923.csv
Study Period: 2023-01-01 to 2025-10-28
Key FDA Dates: Resmetirom (Mar 14, 2024), Semaglutide (Aug 15, 2025)

DATA SUMMARY
--------------------
Total Publications: 1344
Publications With Abstracts: 1142
Publications Mentioning Masld: 400
Publications Mentioning Nafld: 175
Publications Mentioning Nash: 130
Publications Mentioning Mash: 197
Publications Mentioning Resmetirom: 237
Publications Mentioning Glp1: 600
Publications Mentioning Masld Resmetirom: 100
Publications Mentioning Masld Glp1: 94
Unique Journals: 620
Date Range Start: 2023-01-01 00:00:00
Date Range End: 2026-01-01 00:00:00

KEY FINDINGS
--------------------
MASLD was mentioned in 400 publications (29.8% of total)
NAFLD was mentioned in 175 publications (13.0% of total)
Resmetirom was mentioned in 237 publications (17.6% of total)
GLP-1 agonists were mentioned in 600 publications (44.6% of total)
MASLD + Resmetirom combined mentions: 100 publications
MASLD + GLP-1 combined mentions: 94 publications

FILES GENERATED
--------------------
Visualizations:
  - pubmed_publication_trends.png
  - pubmed_term_mentions.png
  - pubmed_terminology_adoption.png
  - pubmed_top_journals.png

Data Tables:
  - pubmed_summary_statistics.csv
  - pubmed_yearly_statistics.csv
